Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Express Scripts
Merck
Johnson and Johnson
Colorcon

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0152

See Plans and Pricing

« Back to Dashboard

What is the drug development status for GDC-0152?

GDC-0152 is an investigational drug.

There have been 163 clinical trials for GDC-0152. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are seven US patents protecting this investigational drug and one hundred and eighteen international patents.

Recent Clinical Trials for GDC-0152
TitleSponsorPhase
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the BonesNational Cancer Institute (NCI)Phase 2
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerNational Cancer Institute (NCI)Phase 1/Phase 2

See all GDC-0152 clinical trials

Clinical Trial Summary for GDC-0152

Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152

See all GDC-0152 clinical trials

US Patents for GDC-0152

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0152   Start Trial Inhibitors of IAP Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0152   Start Trial Inhibitors of IAP Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0152   Start Trial Inhibitors of IAP Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0152   Start Trial Inhibitors of IAP Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0152   Start Trial Inhibitors of IAP GENENTECH, INC. (South San Francisco, CA)   Start Trial
GDC-0152   Start Trial Biomarkers for IAP inhibitor therapy Novartis AG (Basel, CH)   Start Trial
GDC-0152   Start Trial Inhibitors of IAP GENENTECH, INC. (South San Franscisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0152

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0152 Australia 2005270104 2024-07-02   Start Trial
GDC-0152 Australia 2009243421 2024-07-02   Start Trial
GDC-0152 Australia 2011236020 2024-07-02   Start Trial
GDC-0152 Australia 2012241077 2024-07-02   Start Trial
GDC-0152 Brazil PI0511350 2024-07-02   Start Trial
GDC-0152 Canada 2570321 2024-07-02   Start Trial
GDC-0152 China 101035802 2024-07-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Mallinckrodt
Moodys
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.